期刊文献+

卵巢恶性肿瘤合并VTE患者的相关指标分析研究

Analysis of relevent factors of patients with malignant ovarian tumor and venous thromboembolism
下载PDF
导出
摘要 目的探讨卵巢恶性肿瘤合并静脉血栓栓塞症(VTE)患者的相关指标。方法回顾性分析入住我院的50例卵巢恶性肿瘤患者的病例资料,其中25例合并VTE患者为观察组,选取同期不合并VTE的患者25例作为对照组。结果观察组PLT,D-二聚体和腹水量明显高于对照组(P<0.05);观察组肿瘤直径、CA125、CA199、HE4、AFP和CEA同对照组比较,P均>0.05。结论卵巢恶性肿瘤合并VTE患者PLT及D-二聚体显著增高,腹水量增加。 Objective To explore the biomarkers and relevent risk factors of patients with malignant ovarian tu⁃mor and venous thromboembolism.Methods The clinical data of 50 patients with ovarian malignant tumor admitted to our hospital were analyzed retrospectively.Among them,25 patients with VTE were in the observation group and 25 pa⁃tients without VTE were in the control group.Results The PLT,D-dimer and ascites quantity in the observation group were obviously higher than those in the control group(P<0.05).The tumor diameter,CA125,CA199,HE4,AFP and CEA in the observation group had no significant difference from those in the control group(P>0.05).Conclusion Great increase of PLT,D-dimer and ascites quantity were high risk factors for VTE in patients with malignant ovarian cancer.
作者 闫华 鞠永静 王增艳 刘洪云 代艳芬 冯富忠 YAN Hua;JU Yongjing;WANG Zengyan;LIU Hongyun;DAI Yanfen;FENG Fuzhong(Linyi Central Hospital,Linyi 276400,Shandong)
机构地区 临沂市中心医院
出处 《菏泽医学专科学校学报》 2020年第2期13-15,共3页 Journal of Heze Medical College
基金 临沂市2019年科技创新发展计划。项目编号:201919030。
关键词 卵巢恶性肿瘤 VTE 生物指标 Malignant ovarian cancer Venous thromboembolism Biomarker
  • 相关文献

参考文献2

二级参考文献33

  • 1HANAHAN D, WEINBERG R A. Hallmarks of cancer: the next generation [J]. Cell, 2011,144(5): 646-674. 被引量:1
  • 2LEE J S, HEO J, LIBBRECHT L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from he- patic progenitor cells [J]. Nat Med, 2006, 12(4): 410-416. 被引量:1
  • 3YAMASHITA T, FORGUES M, WANG W, et al. EpCAM and alphafetoprotein expression defines novel prognostic sub- types of hepatocellular carcinoma [J]. Cancer Res, 2008, 68(5): 1451-1461. 被引量:1
  • 4FORNER A, LLOVET J M, BRUIX J. Hepatocellular carci- noma [J]. Lancet, 2012, 379(9822): 1245-1255. 被引量:1
  • 5BRUIX J, LLOVET J M. Prognostic prediction and treatment strategy in hepatocellular carcinoma [J]. Hepatology, 2002, 35(3): 519-524. 被引量:1
  • 6SHIBATA T, ABURATANI H. Exploration of liver cancer ge- nomes [J]. Nat Rev Gastroenterol Hepatol, 2014, 11(6): 340- 349. 被引量:1
  • 7MIAO R, LUO H, ZHOU H, et al. Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcino- ma and stratification by integrative multi-omics analysis [J]. J Hepatol, 2014, 61(4): 840-849. 被引量:1
  • 8IKEDA A, SHIMIZU T, MATSUMOTO Y, et al. Leptin Re- ceptor Somatic Mutations Are Frequent in HCV-Infected Cir- rhotic Liver and Associated With Hepatocellular Carcinoma [J]. Gastroenterology, 2014, 146(1): 222-232, e235. 被引量:1
  • 9HUANG J, DENG Q, WANG Q, et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma [J]. Nat Genet, 2012, 44(10): 1117-1121. 被引量:1
  • 10GAO Q, WANG X Y, ZHOU J, et al. Multiple carcinogenesis contributes to the heterogeneity of HCC [J]. Nat Rev Gastro- enterol Hepatol, 2015, 12(1): 13. 被引量:1

共引文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部